iShares Biotechnology ETF IBB
218.92 USD +3.45 (+1.60%)
Nov 4, 2026, 2:56 PM EST
214.04 Day range 220.46
156.08 52-week range 218.95
- YTD
- +29.71%
- 1 year
- +40.26%
- Market cap
- 11.37B
- EPS (ttm)
- 8.00
- P/E ratio
- 27.35
- Dividend yield
- 0.16%
- YTD return
- +29.71%
- 1-year return
- +40.26%
- Volume
- 1.39M
- Avg volume
- 1.66M
- Open
- 220.10
- Previous close
- 215.47
- Day's range
- 214.04 – 220.46
- 52-week range
- 156.08 – 218.95
2Y +76.43 (+53.50%)
Key statistics
- Enterprise value
- 0
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- 0
- Total cash
- 0
- Total debt
- 0
- Return on equity
- 0.00%
- Short % of float
- 0.00%
- 50-day average
- 208.43
- 200-day average
- 184.97
Next earnings
Consensus EPS estimate 0.00.
About iShares Biotechnology ETF
The fund generally will invest at least 80% of its assets in the component securities of its underlying index and may invest up to 20% of its assets in certain futures, options and swap contracts, cash and cash equivalents. It is non-diversified.
News
Is iShares Biotechnology ETF (IBB) a Strong ETF Right Now? 
$10,000 in Vanguard's Health Care ETF in 2004 Grew to $93,915, and It Still Charges 0.09% 
Alphabet Posts Worst Week Since 2011, Intel Suffers Record Crash as Warsh Sees 'Cracks': This Week on Wall Street 
Regeneron Surges 13.55%: Here's What It Means for Your Health Care ETFs 
Should You Invest in the iShares Biotechnology ETF (IBB)? 
ETFs That You May Consider Amid a Strengthening Biotech Outlook 
Invesco's RSPH or iShares' IBB: Which Healthcare ETF Is the Better Long-Term Buy? 
Biotech stocks are surging. How investors can play the new drug innovation boom 
Invesco Pharmaceuticals ETF vs. iShares Biotechnology ETF: Which Is the Better Buy? 
iShares Biotechnology ETF $IBB Shares Sold by Fairvoy Private Wealth LLC
Your note
Sign in to keep a note on IBB — it syncs with the Stock Master app.